Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia

Haematologica

Volumn 88, Issue 11, 2003, Pages 1204-1212

  Sagaster, Verena ^a   Jäger, Eva ^d   Weltermann, Ansgar ^a   Schwarzinger, Ilse ^b   Gisslinger, Heinz ^a   Lechner, Klaus ^a   Geissler, Klaus ^c   Oehler, Leopold ^a,b  

^a Division of Hematology   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c GENERAL HOSPITAL LINZ   (Austria)

^d NONE

Author keywords

Circulating hematopoietic progenitor cells; Myelofibrosis with myeloid metaplasia; Survival

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER RISK; CONTROLLED STUDY; ERYTHROID CELL; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PREDICTION; PROGNOSIS; REGRESSION ANALYSIS; STEM CELL; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD CELL COUNT; COLONY-FORMING UNITS ASSAY; ERYTHROID PROGENITOR CELLS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELLS; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; MYELOID CELLS; MYELOID METAPLASIA; PLATELET COUNT; PLURIPOTENT STEM CELLS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETICULOCYTE COUNT; SPLENOMEGALY; SURVIVAL ANALYSIS;

EID: 0345659202     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:375-6.
2. Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Haematol 1975;4:409-28.
3. Manoharan A. Annotation: myelofibrosis: prognostic factors and treatment. Br J Hematol 1988;69:295-8.
4. Hasselbalch H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol 1990;34:291-300.
5. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. Ann Hematol 1991;63:101-6.
6. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-70.
7. Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda R-C. Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol 2000;79:312-8.
8. Chervenick PA. Increase in circulating stem cells in patients with myelofibrosis. Blood 1973;41:67-71.
9. Chikkappa G, Carsten AL, Chanana AD, Chandra P, Cronkite EP. Increased granulocytic, erythrocytic, and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia. Am J Hematol 1978;4:121-31.
10. Croizat H, Amato D, McLeod DL, Eskinazi D, Axelrad AA. Differences among myeloproliferative disorders in the behavior of their restricted progenitor cells in culture. Blood 1983;62:578-84.
11. Douer D, Fabian I, Cline M-J. Circulating pluripotent haematopoietic cells in patients with myeloproliferative disorders. Br J Haematol 1983;54:373-81.
12. Hibbin JA, Njoku OS, Matutes E, Lewis SM, Goldman JM. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol 1984;57:495-503.
13. Andreasson B, Swolin B, Kutti J. Increase of CD34 positive cells in polycythaemia vera. Eur J Haematol 1997;59:171-6.
14. + cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol 2002;68:189-93.
15. Besa EC, Nowell PC, Geller NL, Gardner FH. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 1982;49:308-13.
16. Foa P, Maiolo AT, Cortellaro M, Ortolani S, Pogliani E, Deliliers GL, et al. 1,25-Dihydroxyvitamin D3 in the treatment of idiopathic thrombocythemia and myelofibrosis. Haematologica 1990;75:294-5.
17. Heis-Vahidi-Fard N, Forberg E, Eichinger S, Chott A, Lechner K, Gisslinger H. Ineffectiveness of interferon-gamma in the treatment of idiopathic myelofibrosis: a pilot study. Ann Hematol 2001;80:79-82.
18. Matsukawa Y. Treatment of idiopathic myelofibrosis. Ann Hematol 2000;79:646-7.
19. Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, et al. Phase 2 trial of imatinib in myelofibrosis with myeloid metaplasia. Blood 2002;99:3854-6.
20. Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arceseet W, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia. Blood 1999;93:2831-8.
21. Njoku O-S, Lewis S-M, Catovsky D, Gordon-Smith C. Anaemia in myelofibrosis: its value in prognosis. Br J Hematol 1983;54:79-89.
22. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasma. Br J Haematol 1988;70:397-401.
23. Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, et al. Myelofibrosis with myeloid metaplasia: clinical and hematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990;75:4-9.
24. Hasselbalch H, Jensen BA. Prognostic factors in idiopathic myelofibrosis: a simple scoring system with prognosic significance. Eur J Haematol 1990;44:172-8.
25. Anger B, Seidler R, Haug U, Popp C, Heimpel H. Idiopathic myelofibrosis: a retrospective study of 103 patients. Haematologica 1990;75:228-34.
26. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 2000;85:1126-34.
27. Dupriez B, Morel P, Demory J-L, Simon M, Plantier I, Bauters F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013-18.
28. Oehler L, Foedinger M, Koeller M, Kollars M, Reiter E, Bohle B, et al. Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogeneous granulocyte-macrophage colony-stimulating factor release. Blood 1997;89:1147-53.
29. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988;28:1194-8.
30. + cells in myelofibrosis with myeloid metaplasia. Blood 2001;98:3249-55.
31. Ruutu T, Partanen S, Litula R, Teerenhovi L, Knuutila S. Erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Scand J Haematol 1984;32:395-402.
32. Tennant GB, Jacobs A, Bailey-Wood R. Peripheral blood granulocyte-macrophage progenitors in patients with the myelodysplastic syndromes. Exp Hematol 1986;14:1063-68.
33. Fuchigami K, Mori H, Matuso T, Iwanaga M, Nagai K, Kuriyama K, Tomonaga M. Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in REAB and REAB-t; novel pathologic features of myelodysplastic syndromes identified by high sensitive flow cytometry. Leuk Res 1999;24:163-74.
34. Öhler L, Berer A, Aletaha D, Kabrna E, Heinze G, Streubel B, et al. Cytogenetic risk groups in acute myeloblastic leukaemia differ greatly in their semi-solid colony growth. Br J Haematol 2001;113:120-5.
35. Öhler L, Geissler K. Semi-solid colony growth in acute myeloid leukemia and its relation to cytogenetic risk groups. Leuk Lymphoma 2002;43:1743-7.
36. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001;113:763-71.